Disease progression in dementia with Lewy bodies:
A longitudinal study on clinical symptoms, quality of life and functional impairment

Marleen van de Beek1 | Annemartijn van Unnik1 | Inger van Steenoven1 | Jessica van der Zande1 | Frederik Barkhof2,3 | Charlotte E. Teunissen4 | Wiesje van der Flier1,5 | Afina W. Lemstra1

1Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
2Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands
3Institutes of Neurology and Healthcare Engineering, UCL, London, England, UK
4Department of Clinical Chemistry, Neurochemistry Laboratory, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
5Department of Epidemiology and Data Sciences, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

Correspondence
Marleen van de Beek, Department of Neurology, Alzheimer Center Amsterdam, Amsterdam UMC, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.
Email: m.vandebeek2@amsterdamumc.nl

Abstract
Background and Objectives: Dementia with Lewy Bodies (DLB) is a heterogeneous disease, with variable signs and symptoms across multiple domains. We aimed to identify associations with rate of change in cognition, everyday functioning (IADL) and quality of life (QoL).

Methods: We included 121 DLB patients (69 ± 6 yrs, 14%F, MMSE: 25 ± 3) in our prospective cohort (follow-up 2 ± 1 yrs). We described progression of symptoms and cognitive decline over time. Mixed models were used to investigate whether changes in symptoms were associated to changes in IADL (FAQ), QoL (QoL-AD) and caregiver burden (ZBI). Last, we investigated whether baseline symptoms and biomarkers predicted decline in cognition (MMSE), IADL (FAQ) and QoL (QoL-AD).

Results: Parkinsonism and RBD were most frequently present early in the disease course, while hallucinations were more likely to develop in a later stage. MMSE (annual change $\beta \pm SE = -2.06 \pm 0.23$), QoL-AD ($-1.03 \pm 0.20$), and FAQ ($3.04 \pm 0.30$) declined over time. Increasing severity of clinical symptoms was associated to increases in FAQ, QoL-AD and caregiver burden. Baseline clinical symptoms were not predictive for decline in these outcomes. By contrast, AD co-pathology (CSF pTau/Ab42 ratio) was associated to steeper decline in MMSE ($-1.23 \pm 0.54$). Medial temporal atrophy ($-0.81 \pm 0.26$) and global cortical atrophy ($-0.73 \pm 0.36$) predisposed for decline in QoL-AD.

Conclusions: Our findings imply that underlying disease processes, rather than clinical symptomatology aid in predicting decline. These findings are relevant for treatment strategies and the development of DLB specific outcome measures.

Keywords
dementia with Lewy bodies, IADL, progression, quality of life
INTRODUCTION

Patients with dementia with Lewy Bodies (DLB) have a highly variable presentation of symptoms. The cognitive profile of DLB is characterized by impairment in attention, executive and visuospatial functions, and fluctuations. Besides cognitive impairment, patients may experience neuropsychiatric symptoms, such as visual hallucinations, delusions, apathy, and depressive symptoms. Other DLB features include physical symptoms, namely parkinsonism, RBD and autonomic dysfunction. Different symptoms have different effects on disease burden, as neuropsychiatric symptoms are associated with reduced quality of life (QoL), while cognitive and physical symptoms have been related to impairment in daily living (IADL).

DLB has an unfavorable prognosis when compared to Alzheimer’s disease (AD). Patients with DLB have more rapid cognitive decline, higher mortality risk and earlier nursing home admission. Former studies estimating disease trajectories in DLB were often limited to estimating global cognitive decline, while it is debatable whether this is the most relevant measure of disease burden from the patients’ perspective. When providing treatment, the ultimate goal is to optimize patients’ QoL and limit impairment in daily living. As such, it is essential to gain insight into how progression of symptoms affects these outcomes. Increased understanding of the contribution of symptoms to disease burden could give targets for symptomatic treatment.

In the present study, we described the progression in symptoms and cognitive domains over time. We aimed to assess how changes in symptoms are associated with changes in functional outcomes and QoL. Last, we aimed to identify factors that influence progression in functional outcomes (cognition, IADL and QoL).

METHODS

We included 121 patients with DLB (n = 91) and MCI due to Lewy Bodies (MCI-LB) (n = 30) from the DEvELOP cohort, embedded within the Amsterdam Dementia cohort. In short, patients were referred to Alzheimer Center Amsterdam and underwent diagnostic screening for dementia that included neurological, physical and neuropsychological evaluation, brain imaging, laboratory work and lumbar puncture. Diagnoses were made in a multidisciplinary meeting. In the case of DLB or MCI-LB diagnosis, patients were invited to participate in DEvELOP. Exclusion criteria were severe physical or life-threatening conditions and nursing home admittance. All patients gave written informed consent for use of their clinical data. The local medical ethics committee approved the study.

2.1 | Clinical follow-up

The first patient was included in 2016 and follow-up is still ongoing. Patients were invited for annual follow-up, during which the clinical workup was repeated. All patients were invited for at least one 1 year follow-up and 92% of the patients that were still available for follow-up had 2 follow-up visits. For MCI-LB patients, their diagnosis was re-evaluated during these follow-up visits. Progression to dementia was defined as having two or more impaired cognitive domains at neuropsychological assessment, accompanied by interference in daily living.

2.2 | Clinical measures

Within DEvELOP, several questionnaires were administered to evaluate core and suggestive symptoms, IADL and QoL. The operationalization of symptoms and outcomes used in this study are summarized in Table 1. Duration of complaints was assessed during the patients’ first visit and was operationalized as the time between diagnosis and the moment when the patient first noticed their cognitive complaints. Parkinsonism was assessed with the Movement disorders society Unified Parkinson’s disease rating scale—UPDRS III (motor subscale). Parkinsonism was rated as present when the patient had bradykinesia (UPDRS-bradykinesia≥1) with additional rigidity (≥1) and/or resting tremor (≥1). Subscales of the Neuropsychiatric Inventory (NPI) were used to assess presence of hallucinations, delusions, anxiety and apathy (cutoff per subscale ≥1). Presence of fluctuations was assessed using the Mayo Fluctuations questionnaire (MFQ, cutoff ≥3). RBD was assessed with the Mayo Sleep questionnaire (MSQ, cutoff ≥1). We used the Geriatric Depression Scale (GDS) 15-items as a measure of depressive symptoms. Severity of orthostatic hypotension was defined by the difference in systolic blood pressure between lying and 3 min after standing. Constipation and urinary problems were assessed with the Non Motor Symptoms Scale (NMSS) or with the SCOPA-AUT (n = 22). We dichotomized presence of symptoms with the NMSS questions 21 and 22 SCOPA-AUT questions 5 and 8.
## Table 1  Baseline characteristics and annual change in symptoms

|                           | N = 121                                      |
|---------------------------|---------------------------------------------|
| **Sex, n female (%)**     | 17 (14%)                                    |
| **Age, years**            | 69 ± 6                                       |
| **Duration of complaints, years** | 3 [2-5]                               |
| **Syndrome diagnosis, MCI/dementia** | 30/91 (25%/75%)                           |
| **Education, years**      | 12 ± 3                                       |
| **Follow-up duration, years** | 2 ± 1                                        |
| **Loss to follow-up, n (%)** | 55 (45%)                                   |
| **Time to loss to follow-up** | 2.0 ± 0.9                               |
| **Core clinical symptoms** |                                            |
| **MMSE**                  | 25 ± 3                                       |
| **Hallucinations, (NPI, frequency*severity, n = 109)** | 1.39 ± 2.68 |
| **Hallucinations, n present (%)** | 43 (38%)                                    |
| **Parkinsonism (UPDRS, n = 118)** | 21 ± 12                                    |
| **Fluctuations (MFQ, n = 116)** | 2 [1-3]                                    |
| **RBD (MSQ, n = 117)**    | 87 (74%)                                     |
| **OH (drop SBP, n = 119)** | 20 ± 21                                      |
| **Urinary (NMSS/SCOPA-AUT, n = 119)** | 59 (49%)                                    |
| **Constipation (NMSS/SCOPA-AUT, n = 119)** | 44 (37%)                                    |
| **Delusions, (NPI, frequency*severity, n = 109)** | 0.56 ± 2.01 |
| **Delusions, n present (%)** | 13 (11%)                                    |
| **Apathy (NPI, frequency*severity, n = 109)** | 2.89 ± 3.14 |
| **Apathy, n present (%)** | 69 (60%)                                     |
| **Anxiety (NPI, frequency*severity, n = 109)** | 1.43 ± 2.16 |
| **Anxiety, n present (%)** | 52 (45%)                                     |
| **Depressive symptoms (GDS, n = 115)** | 4 ± 3                                        |
| **Disease burden**        |                                            |
| **IADL (FAQ)**            | 12 ± 6                                       |
| **Quality of life (QoL-AD)** | 31 ± 5                                      |
| **Caregiver burden (ZBI)** | 24 ± 15                                     |
| **Biological measurements** |                                              |
| **CSF pTau/AB42 ratio abnormal (n = 83)** | 48 (58%)                                    |
| **DAT-scan, abnormal (n = 95)** | 83 (87%)                                    |
| **APOE-e4 carrier (n = 90)** | 45 (50%)                                    |
| **MTA, median [IQR]**     | 1 [0–2]                                      |
| **Global cortical atrophy, median [IQR]** | 1 [0–1]                                    |
| **EEG abnormal, n (%)**   | 78 (96%)                                     |

Note: Data represent mean ± SD, n (%) or median [IQR]. Annual change in scores was estimated with linear mixed models, data represent β ± SE *p < 0.05, **p < 0.001.

Abbreviations: FAQ, Functional activities questionnaire; GDS, Geriatric depression scale; MFQ, Mayo Fluctuations Questionnaire; MMSE, Mini-Mental State Examination; MSQ, Mayo Sleep Questionnaire; NMSS, non motor symptoms scale; NPI, neuropsychiatric inventory; QoL-AD, Quality of Life—Alzheimer’s disease; SBP, systolic blood pressure; UPDRS, Unified Parkinson’s disease rating scale.
IADL interference was measured with the Functional activities questionnaire (FAQ, range 0–30). Higher scores indicate higher interference and a score higher than 7 is indicative of cognitive impairment.\(^\text{14,17}\) QoL measured with the Quality of Life-AD (QoL-AD) questionnaire (range 0–30) with higher scores indicating higher QoL.\(^\text{18}\) Caregiver burden was measured with the Zarit burden interview (ZBI, range 0–88). Scores higher than 21 indicate mild to moderate caregiver burden, and high.\(^\text{19}\)

### 2.3 Neuropsychological assessment

At baseline and follow-up, patients underwent extensive neuropsychological assessment. We used MMSE as a measure of global cognition. Attention was assessed using the Trail-Making Test-A (TMT-A), Stroop-I and Stroop-II and digit span-forward.\(^\text{20-22}\) Memory functioning was measured with the Dutch version of the Rey Auditory Verbal Learning test (RAVLT, immediate and delayed recall), the Visual Association Test version A (VAT-A) and the 3 min delayed recall of the Rey complex figure.\(^\text{23-25}\) Executive functioning was measured with TMT-B (ratio TMT-B/TMT-A), Stroop-III (ratio Stroop-III/Stroop-II), digit span backwards (corrected for digit span forward), the Frontal Assessment Battery and letter fluency tests.\(^\text{21,22}\) Visuospatial functioning was assessed using three subtests of the Visual Object and Space Perception battery (number location, fragmented letters, dot counting) and the copy of the Rey complex figure.\(^\text{25,26}\) Language was assessed with animal fluency and VAT-naming subtest.\(^\text{24,27}\) Time dependent tests were inverted so that higher scores reflect better performance. We calculated z-scores using the baseline data as a reference. Next, we created composite scores by calculating the average Z-score of each test in the domain. Composite scores were only calculated if at least two tests in the corresponding domain were available.

### 2.4 Baseline biological measures

MRI scanning was performed according to the standardized dementia protocol and visual assessment of atrophy was performed by experienced neuroradiologists.\(^\text{9}\) Medial temporal lobe atrophy (MTA) was rated using coronal T1-weighted images on a 5-point scale (0–4).\(^\text{28}\) Global cortical atrophy (GCA) was rated on axial images using a 4-point scale (0–3).\(^\text{29}\) Baseline MRI was available for \(n = 109\) (90%) patients.

CSF Aβ42, Tau and pTau concentrations were measured using a sandwich ELISA (Innotest, Fujirebio), or the Elecsys Aβ42, Tau, and pTau (181P) CSF assays run on the cobas e601 analyzer (Roche Diagnostics GmbH). Concomitant AD pathology was defined as a ratio of pTau/Aβ42 > 0.054 (Innotest) or pTau/Aβ42 > 0.020 (Elecsys).\(^\text{30}\) Baseline CSF was available for \(n = 83\) (69%) patients.

Dopamine transporter imaging (\(^{123}\)FP-CIT(DAT)-SPECT) was performed on discretion of the clinician to confirm diagnosis and was available for \(n = 95\) (79%) patients. The SPECT imaging protocol has been described in detail in a previous report.\(^\text{31}\) Visual assessments and age-matched BRs were taken into account in determining whether the scan was normal or abnormal.\(^\text{31}\)

EEGs were recorded as standard screening of the memory clinic using a digital EEG system and software (Brain RT®; OSG b.v.). The EEG registrations were visually assessed by certified neurophysiologists and were scored according to a standardized visual rating scheme.\(^\text{32}\) From this scheme, the 5 point scale to assess the severity of EEG abnormalities was used, in which a severity score of higher than 1 indicated an abnormal EEG. EEG was available for \(n = 81\) (67%) patients.

### 2.5 Statistical analyses

Analyses were performed in Rstudio 4.0.3. First, we used descriptive statistics to describe baseline characteristics and the longitudinal aspects of our cohort. For longitudinal analyses, we visualized the occurrence and likelihood of developing core clinical symptoms over time using cox proportional hazards analyses. We used the first occurrence of the symptom as an event and used the time between the baseline visit and the visit of the first occurrence as time. Longitudinal changes in severity of symptoms, cognition, IADL, QoL and caregiver burden were assessed with linear mixed models analyses (LMM). We created separate models per outcome of interest (dependent variable). These models included variables of interest as dependent variables, with time added as a fixed factor and random factors for individual intercept and time.

Next, to investigate how changes in symptoms related to changes in outcomes, we calculated difference scores (delta (Δ) scores) of symptom scores and outcomes between visits (Δ symptom = ‘symptom score at t’, minus ‘symptom score at t-1’). We standardized these deltascores to make comparisons between predictors possible. Standardization was performed by making Z-scores of delta-scores ((delta score—mean delta score)/SD). LMMs were performed, accounting for repeated measures, with Δ symptoms as fixed factors and Δ outcome (ΔFAQ, ΔQoL, ΔZBI) as dependent variables and included a random intercept.

To identify which baseline measures were associated to decline in cognition, IADL and QoL over time, we applied LMMs with an interaction between time and the potential baseline determinants. We performed separate models for clinical symptoms (UPDRS-III motor score, NPI-hallucinations, MFQ, GDS, MSQ), and biological determinants (CSF AD profile (yes/no), EEG (abnormal yes/no), DAT-SPECT (abnormal yes/no), MTA, GCA). Models included time, age and sex as fixed factors, and included a random intercept and random slope for time. \(p\)-values were corrected for multiple testing with the FDR method. Significance was set at \(p < 0.05\).

### 3 RESULTS

At baseline, participants were 69 ± 6 years old, 14% were female and MMSE was 25 ± 3. Mean duration of follow-up was 2 ± 1 years (Table 1). Of 26 MCI-LB patients with at least one follow-up visit, 15
(58%) progressed to dementia after 1.5 ± 0.9 years. Of 121 patients, n = 14 patients completed the 4-year follow-up and for n = 53 patients follow-up is still ongoing. Reasons for loss-to-follow-up were death (n = 16, mean time to death 1.7 ± 0.9 years), nursing home admission (NAH) (n = 21, mean time to NAH 2.5 ± 0.8 years) or disease burden (n = 17, mean time to loss to follow-up 1.8 ± 1.0 years).

3.1 | Longitudinal symptoms, functional outcomes and cognition

At baseline, mean UPDRS-III was 21 ± 12 and 75% of patients fulfilled criteria for parkinsonism (bradykinesia with additional tremor and/or rigidity). The severity of parkinsonism increased over time (annual change UPDRS-III: β ± SE = 5.37 ± 0.55) and the likelihood of having parkinsonism after 2 years follow-up was nearly 100% (Figure 1). NPI-hallucinations was indicative for presence of hallucinations in 38% patients at baseline. The NPI-hallucinations score increased over time (annual change NPI-hallucinations: β ± SE = 0.44 ± 0.16). The cumulative likelihood of having hallucinations was over 75% after 3 years follow-up. Median MFQ was 2 (IQR 1–3), 39% of patients had an MFQ indicative of presence of fluctuations. The likelihood of having fluctuations was lowest of all symptoms and remained at 70% after 2 years follow-up. RBD, self-reported or caregiver-reported RBD symptoms were present in 74% of patients, this slightly increased over time, up to 82%.

For suggestive symptoms, we found that at baseline, nearly half of the patients (49%) had urinary problems and 37% had signs of constipation. Suggestive neuropsychiatric symptoms were common, 60% of the caregivers reported apathy (NPI frequency * severity: 2.9 ± 3.1), 45% reported anxiety (NPI frequency * severity: 1.4 ± 2.6), Delusions were present in 11% of patients (NPI frequency * severity: 0.6 ± 2.0). Mean GDS was 4 ± 3. Over time, severity and frequency increased for delusions (annual change β ± SE = 0.33 ± 0.11), anxiety (β ± SE = 0.32 ± 0.14) and depressive symptoms (β ± SE = 0.24 ± 0.11). Apathy scores did not show a significant increase.

3.2 | Longitudinal functional outcomes and cognition

IADL dependency increased during follow-up, with an increase of 3.04 ± 0.30 points per year on the FAQ. Likewise, we observed a decrease in QoL over time (β ± SE = −1.03 ± 0.19). Caregiver burden increased over time, with 3.43 ± 0.58 annual increase on the ZBI. MMSE declined over time (annual change: β ± SE = −2.06 ± 0.23). When comparing different cognitive domains, we found that all cognitive domains declined over time (Figure 2). The steepest decline was observed in the attention domain (β ± SE = −0.62 ± 0.07). On individual tests, TMT-A (β ± SE = −0.79 ± 0.10) and Stroop-II (β ± SE = −0.84 ± 0.12) showed steepest decline.

3.3 | Changes in symptoms relate to changes in IADL and QoL

We applied LMM on repeated delta scores per individual to assess whether changes in symptoms were related to changes in functional outcomes (Table 2). Decline in MMSE and increases in parkinsonism, visual hallucinations, fluctuations and orthostatic hypotension were associated to a stronger increase in IADL dependency, of which fluctuations showed strongest association. We found that changes in depressive symptoms paired with decline in QoL, but this association

![Figure 1](https://example.com/figure1.png) Cumulative likelihood of the presence of core clinical features during the course of the follow-up, as calculated with cox-proportional hazards. RBD, rapid eye movement sleep behavior disorder.

![Figure 2](https://example.com/figure2.png) Cognitive domains over time. Data are Z-transformed using baseline values as reference. Slopes are estimated with linear mixed models, corrected for age and sex.
did not survive FDR correction. Increases in fluctuations and hallucinations were associated to increases in caregiver burden, the latter association did not survive FDR correction.

### 3.4 Factors that influence disease progression

Table 3 displays the estimated association between baseline symptomatology and biological measures on baseline cognition (MMSE), IADL (FAQ) and QoL (QoL-AD) and decline on these measures over time. In line with previous work, we found several associations to baseline functional outcomes. Longitudinally, lower NPI-hallucinations scores at baseline were associated to stronger increase of IADL dependency over time. Other clinical symptoms were not predictive of decline on MMSE, IADL or QoL over time. By contrast, several abnormalities on biological measures predisposed for decline on functional outcomes. Specifically, concomitant AD pathology (abnormal CSF pTau/Aβ42 ratio) was related to stronger decline on MMSE. Medial temporal and GCA were associated to steeper rate of decline in QoL. There were no significant associations of any of the determinants and change in FAQ.

### 4 DISCUSSION

In our prospective DLB cohort we observed worsening of symptoms and cognitive impairment, which was associated with increases in disease burden. Biomarkers of AD pathology and neurodegeneration at baseline were more predictive of the rate of decline of cognitive functioning, functional impairment and QoL than baseline clinical symptoms. Still, the degree of progression of clinical symptoms over time was related to progression in functional outcomes. Our findings have implications for therapeutic treatment strategies and give targets for the development of DLB specific outcome measures.

Congruent with previous studies, AD copathology was related to steeper cognitive decline.

| Δ Cognition (MMSE) | Δ FAQ | Δ QoL-AD | Δ ZBI |
|-------------------|-------|---------|-------|
| Δ Parkinsonism (UPDRS) | 0.18 ± 0.08** | -0.08 ± 0.07 | 0.10 ± 0.09 |
| Δ Hallucinations (NPI) | 0.23 ± 0.08** | -0.11 ± 0.08 | 0.16 ± 0.08* |
| Δ Fluctuations (MFQ) | 0.33 ± 0.07** | -0.12 ± 0.08 | 0.24 ± 0.08** |
| Δ RBD (MSQ) | 0.02 ± 0.07 | 8.81 ± 12.29 | -0.08 ± 0.07 |
| Δ Orthostatic hypotension (yes/no) | 0.17 ± 0.08* | -0.12 ± 0.08 | -0.05 ± 0.09 |
| Δ Depressive symptoms (GDS) | 0.05 ± 0.08 | -0.18 ± 0.08* | -0.09 ± 0.08 |

Note: Data represent β ± SE as estimated by linear mixed models, using difference (Δ) scores between follow-up moments for outcomes and predictors per individual. To enable comparison, difference scores were standardized before analyses. Bold depicts significant associations. *p < 0.05, **p < 0.5 after FDR correction.

Abbreviations: FAQ, Functional activities questionnaire; GDS, Geriatric depression scale; MFQ, Mayo Fluctuations Questionnaire; MSQ, Mayo Sleep Questionnaire; NPI, neuropsychiatric inventory; QoL-AD, Quality of Life—Alzheimer’s disease; SBP, systolic blood pressure; UPDRS, Unified Parkinson’s disease rating scale; ZBI, Zarit burden interview.
only mildly increased. It could be that the MFQ lacks sensitivity to capture changes in fluctuations, as it does not take into account fluctuation severity. On the other hand, increasing MFQ scores were associated to increases in IADL dependency and caregiver burden, suggesting that increasing presence of fluctuations impacts daily living of both patients and caregivers. This underlines the importance of carefully assessing fluctuations and where possible, provide adequate symptomatic treatment.

Or all core symptoms, parkinsonism and RBD were most likely to be present in the early stages of dementia, while hallucinations developed in a later stage for many of our patients. Progression of clinical symptoms was accompanied by changes in functional outcomes. Although we do not imply a causal relationship, it could be hypothesized that treatment of symptoms would have a beneficial effect on functional outcomes. Guidelines for treating DLB symptoms are available, yet knowledge on the effect of symptom treatment on IADL, QoL and caregiver burden is limited. Future RCTs could shed light on the causal relationship of our findings.

The main strength of this study is the prospective design with thorough and systematic annual clinical assessment. Secondly, this study estimated the trajectories not only in terms of cognitive decline but also incorporated QoL, IADL and caregiver burden over time, outcomes that patients and caregivers identified as relevant outcome measures. Few limitations should be noted. First, although follow-up collection is still ongoing, already more than half of our patients was not able to complete the 4 year follow-up duration, with an average time of 2 years between inclusion and loss-to-follow-up. Patients who were lost to follow-up were in more advanced disease stages at baseline, suggestive of attrition. While the loss to follow-up is a limitation of the study, it also illustrative of the prognosis of DLB. Future studies with larger sample sizes could implement joint modelling, with both functional decline and mortality or nursing home admission included as outcomes. Second, by the observational nature of our cohort, several factors could have influenced progression that were not taken into account. For example, disease progression is likely influenced by the COVID-19 pandemic and its associated lockdown measures. During the pandemic, social contacts and services such as daycare activities or physical therapy were severely restricted. DLB patients might be particularly vulnerable for the psychosocial effects of these restrictions, and it cannot be ruled out that restrictions have accelerated disease progression. We paused the inclusion of patients during the pandemic, but we were able to continue our follow-up measurements (with some delay). Patients were in varying stages of follow-up during the pandemic, making this a difficult variable to take into account in analyses. A last limitation to be mentioned is

### TABLE 3 Baseline predictors of decline in cognition, IADL and quality of life (QoL)

|                      | MMSE Baseline | MMSE Slope | FAQ Baseline | FAQ Slope | QoL-AD Baseline | QoL-AD Slope |
|----------------------|---------------|------------|--------------|-----------|-----------------|--------------|
| Age                  | −0.07 ± 0.05  | −0.00 ± 0.04 | −0.03 ± 0.10 | 0.11 ± 0.05 | 0.14 ± 0.07*    | −0.07 ± 0.03 |
| Sex                  | −3.46 ± 0.79**| −1.12 ± 0.75 | 2.81 ± 1.75  | 0.55 ± 0.99 | 1.09 ± 1.21     | −1.12 ± 0.62 |
| Clinical symptoms    |               |            |              |           |                 |              |
| MMSE                 | −0.98 ± 0.18**| −0.07 ± 0.12 | 0.2 ± 0.14   | 0 ± 0.08  |                 |              |
| Parkinsonism (UPDRS) | −0.06 ± 0.02* | −0.02 ± 0.02 | 0.16 ± 0.05**| −0.02 ± 0.03 | −0.08 ± 0.04*    | −0.01 ± 0.02 |
| Hallucinations (NPI) | −0.19 ± 0.11  | 0.07 ± 0.09  | 0.52 ± 0.23**| −0.24 ± 0.11* | −0.33 ± 0.16*    | 0.13 ± 0.08  |
| Fluctuations (MFQ)   | −0.42 ± 0.25  | 0.06 ± 0.21  | 2.79 ± 0.49**| −0.38 ± 0.28 | −1.09 ± 0.38**    | 0.2 ± 0.19   |
| RBD (MSQ)            | −0.34 ± 0.65  | −0.22 ± 0.58 | 2.36 ± 1.39  | −0.75 ± 0.75 | −0.77 ± 0.99     | 0.55 ± 0.49  |
| Depressive symptoms  | −0.27 ± 0.10**| −0.02 ± 0.09 | 0.73 ± 0.22**| −0.14 ± 0.11 | −0.94 ± 0.14**    | 0.13 ± 0.08  |
| Orthostatic hypotension (drop in SBP) | 0.1 ± 0.56    | −0.53 ± 0.47 | 0.03 ± 1.25  | 0.1 ± 0.63  | −0.8 ± 0.87      | 0.24 ± 0.42  |
| Biological measures  |               |            |              |           |                 |              |
| CSF AD profile       | −0.97 ± 0.65  | −1.23 ± 0.54* | 2.38 ± 1.49  | 1.17 ± 0.67 | −0.35 ± 1.02     | −0.04 ± 0.42 |
| Abnormal EEG         | −3.46 ± 1.64* | −0.03 ± 1.59 | 8.66 ± 3.81**| −1.75 ± 1.85 | −7.6 ± 2.7**     | 1.65 ± 1.23  |
| Abnormal DAT-spect    | −0.83 ± 0.92  | 0.05 ± 0.79  | 0.94 ± 2.08  | 0.39 ± 1.08  | −0.22 ± 1.40     | −0.84 ± 0.67 |
| Medial temporal atrophy | −0.42 ± 0.41  | −0.03 ± 0.31 | 0 ± 0.92    | 0.57 ± 0.40  | 0.68 ± 0.61      | −0.81 ± 0.26**|
| Global cortical atrophy | −1.7 ± 0.51** | 0.05 ± 0.42  | 2.3 ± 1.16*  | 0.48 ± 0.53  | −0.95 ± 0.79     | −0.73 ± 0.36*|

Note: Data represent β ± SE. β baseline = Association between predictor category and baseline outcome (MMSE, FAQ or QoL) β Slope = association with annual decline, as estimated with interaction time*predictor with linear mixed models, corrected for age and sex. Bold depicts significant associations. *p < 0.05, **p < 0.5 after FDR correction.

Abbreviations: FAQ, Functional activities questionnaire; GDS, Geriatric depression scale; MFQ, Mayo Fluctuations Questionnaire; MMSE, Mini-Mental State Examination; MSQ, Mayo Sleep Questionnaire; NPI, neuropsychiatric inventory; QoL-AD, Quality of Life—Alzheimer’s disease; SBP, systolic blood pressure; UPDRS, Unified Parkinson’s disease rating scale.
that the findings are dependent on the measurements that were used, but it is not clear whether all measures are equally respon-
siveness to change. There is no consensus on how to measure DBL
specific symptomatology and progression. A DBL-specific, stan-
dardized set of outcomes would highly improve evaluation of dis-
ease progression and would enhance the potential of comparison
with other studies.

To conclude, we presented the trajectories of cognitive domains
and symptoms in our prospective DBL cohort. We found clinically
relevant associations with disease burden. Biological markers could
help in predicting which patients are at risk for worse prognosis. We
propose that DBL specific outcome measures include a combination
of cognitive measures, specifically tests for attention and processing
speed, and functional measures, like IADL and QoL, as those capture
clinically relevant aspects of the disease spectrum and are sensitive
for decline.

ACKNOWLEDGEMENTS
Research of the Alzheimer Center Amsterdam is part of the Neuro-
degeneration research program of the Neuroscience Campus
Amsterdam. The Alzheimer Center Amsterdam is supported by Alz-
heimer Nederland and Stichting VUMC funds. Afina W. Lemstra, has
received funding from stichting Dioraphte and ZonMW Memorabel
(project #733050509).

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on
request from the corresponding author. The data are not publicly
available due to privacy or ethical restrictions.

ORCID
Marleen van de Beek https://orcid.org/0000-0002-1619-073X

REFERENCES
1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and manage-
ment of dementia with Lewy bodies Fourth consensus report of the
DLB Consortium. Neurology. 2017;89(1):88-100.
2. van de Beek M, van Steenoven I, van der Zande JJ, et al. Charac-
terization of symptoms and determinants of disease burden in de-
mentia with Lewy bodies: DEVELOP design and baseline results.
Alzheim Res Ther. 2021;13(1):1-13.
3. van de Beek M, van Steenoven I, Ramakers IHGB, et al. Trajecto-
yries and determinants of quality of life in dementia with Lewy bodies
and Alzheimer’s disease. J Alzheim Dis. 2019;70(2):387-395.
4. Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of de-
mentia with Lewy bodies. Lancet Neurol. 2017;16(5):390-398.
https://doi.org/10.1016/s1474-4422(17)30074-1
5. Mueller C, Perera G, Rajkumar AP, et al. Hospitalization in people
with dementia with Lewy bodies: frequency, duration, and cost im-
plications. Alzheim Dementia Diagn, Assess Dis Monit. 2018;10(1):
143-152. https://doi.org/10.1016/j.jdadm.2017.12.001
6. Rongve A, Soennensyn H, Skogseth R, et al. Cognitive decline in de-
mentia with Lewy bodies: a 5-year prospective cohort study. BMJ
open. 2016;6(2):e010357. https://doi.org/10.1136/bmjopen-2015-
010357
7. Rongve A, Vossius C, Nore S, Testad I, Aarsland D. Time until nursing
home admission in people with mild dementia: comparison of de-
mentia with Lewy bodies and Alzheimer’s dementia. Int J Geriatr
Psychiatr. 2014;29(4):392-398. https://doi.org/10.1002/gps.4015
8. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the
diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020;
94(17):743-755. https://doi.org/10.1212/wnl.0000000000009323
9. van der Flier WM, Scheltens P. Amsterdam dementia cohort: per-
forming research to optimize care. J Alzheim Dis. 2018;62(3):
1091-1111. https://doi.org/10.3233/jad-170850
10. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rat-
ing Scale (MDS-UPDRS): scale presentation and clinimetric testing.
Mov Disord Off J Mov Disord Soc. 2008;23(15):2129-2170.
https://doi.org/10.1002/mds.22340
11. Cummings JL. The Neuropsychiatric Inventory Assessing psychopa-
thology in dementia patients. Neurology. 1997;48(suppl 6):105-165.
https://doi.org/10.1212/wnl.48.5_suppl_6.10s
12. Walker M, Ayre GA, Cummings JL, et al. The clinician assessment of
fluctuation and the one day fluctuation assessment scale: two
methods to assess fluctuating confusion in dementia. Br J Psychiatry.
2000;177(3):252-256. https://doi.org/10.1192/bjp.177.3.252
13. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent
 evidence and development of a shorter version. Clin Gerontol J Aging
Ment Health. 1986;5(2):165-173. https://doi.org/10.1300/J018v0
5n01_09
14. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric
properties of a novel non-motor symptoms scale for Parkinson’s
disease: results from an international pilot study. Mov Disord.
2007;22(13):1901-1911. https://doi.org/10.1002/mds.21596
15. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of
autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov
Disord Off J Mov Disord Soc. 2004;19(11):1306-1312. https://doi.org/
10.1002/mds.20153
16. Pfeffer RI, Kuroasaki TT, Harrah CH, Chance JM, Filos S. Measurement
of functional activities in older adults in the community. J Gerontol.
1982;37(3):323-329. https://doi.org/10.1037/geront.37.3.323
17. Juva K, Makela M, Erkinjuntti T, et al. Functional assessment scales
in detecting dementia. Age ageing. 1997;26(5):393-400. https://doi.
org/10.1093/ageing/26.5.393
18. Thorgrimsen L, Selwood A, Spector A, et al. Whose quality of life is it
anyway?: the validity and reliability of the Quality of Life-Alzheimer’s
Disease (QoL-AD) scale. Alzheimer Dis Assoc Disord. 2003;17(4):
201-208. https://doi.org/10.1097/00002093-200310000-00002
19. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired
elderly: correlates of feelings of burden. Gerontol. 1980;20(6):
649-655. https://doi.org/10.1037/geront.20.6.649
20. Reitan RM. Validity of the Trail Making Test as an indicator of
organic brain damage. Percept Mot Skills. 1958;8(3):271-276.
https://doi.org/10.2466/pms.8.7.271-276
21. Stroop JR. Studies of interference in serial verbal reactions. J Exp
Psychol Gen. 1992;121(1):15. https://doi.org/10.1037/h0054651
22. Lindeboom J, Matto D. Digit series and Knox cubes as concentration
tests for elderly subjects. J Exp Psychol Hum Learn Mem.
1982;8(3):276-279. https://doi.org/10.1037/h0054651
23. Saan R, Deelman B. Een voorlopig han-
deling. Afdeling Neuropsychologie; 1986.
24. Lindeboom J, Schmand B, Pulker H, Wijndruk H, van Duijvenvoorde M.
Afdeling Neuropsychologie; 1986.
25. Meyer JE, Meyers KR. Rey complex figure test under four different
administration procedures. Clin Neuropsychol. 1995;9(1):63-67.
https://doi.org/10.1080/13854049508402059
26. Warrington E, James M. The Visual Object and Space Perception Battery. Thames Valley Test; 2015.

27. Van Der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc. 2006;12(1):80-89. https://doi.org/10.1017/s1355617706060115

28. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967-972. https://doi.org/10.1136/jnnp.55.10.967

29. Scheltens P, Pasquier F, Weerts JG, Barkhof F, Leys D. Qualitative assessment of cerebral atrophy on MRI: inter-and intra-observer reproducibility in dementia and normal aging. Eur Neurol. 1997;37(2):95-99. https://doi.org/10.1159/000117417

30. Willemsen EAJ. Drift corrected CSF biomarker ratios for tTau: aβ1-42 and pTau: aβ1-42 in the Amsterdam Dementia Cohort. In preparation.

31. Vriend C, Raijmakers P, Veltman DJ, et al. Depressive symptoms in Parkinson’s disease are related to reduced [123]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry. 2014;85(2):159-164. https://doi.org/10.1136/jnnp-2012-304811

32. Liedorp M, van der Flier W, Hoogervorst E, Scheltens P, Stam C. Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. Dementia Geriatr Cognit Disord. 2009;27(1):18-23. https://doi.org/10.1159/000182422

33. Abdelnour C, van Steenoven I, Londos E, et al. Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. Mov Disord. 2016;31(8):1203-1208. https://doi.org/10.1002/mds.26668

34. Lemstra AW, de Beer MH, Teunissen CE, et al. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2017;88(2):113-118. https://doi.org/10.1136/jnnp-2016-313775

35. Kramberger MG, Auestad B, Garcia-Ptacek S, et al. Long-term cognitive decline in dementia with Lewy bodies in a large multicenter, international cohort. J Alzheim Dis. 2017;57(3):787-795. https://doi.org/10.3233/jad-161109

36. Matar E, White SR, Taylor JP, et al. Progression of clinical features in Lewy body dementia can be detected over 6 months. Neurology. 2021;97(10):e1031-e1040. https://doi.org/10.1212/wnl.0000000000012450

37. Kester M, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology. 2009;73(17):1353-1358. https://doi.org/10.1212/wnl.0b013e3181bd8271

38. Tsamakis K, Mueller C. Challenges in predicting cognitive decline in dementia with Lewy bodies. Dementia Geriatr Cognit Disord. 2021;50:1-8. https://doi.org/10.1159/000515008

39. Matar E, Shine JM, Halliday GM, Lewis SJG. Cognitive fluctuations in Lewy body dementia: towards a pathological framework. Brain. 2020;143(1):31-46. https://doi.org/10.1093/brain/awz311

40. Taylor J-P, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157-169. https://doi.org/10.1016/s1474-4422(19)30153-x

41. Mank A, van Maurik IS, Bakker ED, et al. Identifying relevant outcomes in the progression of Alzheimer’s disease; what do patients and care partners want to know about prognosis? Alzheimer Dementia: Translational Research & Clinical Interventions. 2021;7(1):e12189. https://doi.org/10.1002/trc2.12189

42. Killen A, Olsen K, McKeith IG, et al. The challenges of COVID-19 for people with dementia with Lewy bodies and family caregivers. Int J Geriatr Psychiatry. 2020;35(12):1431-1436. https://doi.org/10.1002/gps.5393

43. van Maurik IS, Bakker ED, van den Buse S, et al. Psychosocial effects of corona measures on patients with dementia, mild cognitive impairment and subjective cognitive decline. Front Psychiatr. 2020;11.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: van de Beek M, van Unnik A, van Steenoven I, et al. Disease progression in dementia with Lewy bodies: a longitudinal study on clinical symptoms, quality of life and functional impairment. Int J Geriatr Psychiatry. 2022;1-9. https://doi.org/10.1002/gps.5839